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Department of Drug Design, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
*S Supporting Information
ABSTRACT: The Ugi four-component reaction (U-4CR) with N-
hydroxyimides as a novel carboxylic acid isostere has been reported.
This reaction provides straightforward access to α-hydrazino amides. A
broad range of aldehydes, amines, isocyanides and N-hydroxyimides
were employed to give products in moderate to high yields. This
reaction displays N−N bond formation by cyclic imide migration in the Ugi reaction. Thus, N-hydroxyimide is added as a new
acid component in the Ugi reaction and broadens the scaﬀold diversity.
The Ugi reaction (U-4CR) is a widely used multi-component reaction (MCR) for the synthesis of bis-
amides and peptidomimetics.1 This reaction has emerged as a
powerful synthetic method for the organic, pharmaceutical, and
polymer industries.2 However, it cannot meet the ever-
increasing need for molecular complexity and diversity in
organic and medicinal chemistry. An increasing demand for
novel scaﬀolds has led to the interest in U-4CR post-
modiﬁcations and single-reactant replacement (SRR) by
isosteres.3 U-4CR postmodiﬁcations are useful for the synthesis
of various heterocycles and peptidic scaﬀolds.4 Nevertheless,
isostere use in the Ugi reaction is rather limited.5 An amine
component could be replaced by secondary amines, hydroxyl-
amines, and hydrazines. As with amines, use of acid isosteres in
the Ugi reaction is also limited.
In the Ugi reaction, the carboxylic acid plays several
prominent structural roles, including activation of the
intermediate imine, the reversible addition to the nitrilium
ion, and participation in the irreversible Mumm rearrangement
to form the ﬁnal bis-amide product. Because of carboxylic acid’s
substantial role in the reaction, isosteric replacement by other
agents is diﬃcult to accomplish. In 1962, Ugi reported the ﬁrst
acid isosteric replacements by inorganic acids, such as hydrazoic
acids, cyanates, thiocyanates, etc. (Figure 1).6 To date, only a
few acid isosteres have been reported. For example, our group
reported the thioacetic acid as an isostere.7 El Kaim̈ and co-
workers reported the phenol as an acid isostere in the Ugi
reaction involving Smiles rearrangement to form an N-
arylamine.8 Other Ugi−Smiles and similar strategies have
been described by El Kaim̈ (thiophenol),9 Charton (squaric
acid),10 and Neo (hydroxycoumarins).11 Further, Lewis acids
and CO2 were used as acid isoteres in the U-4CR.
5
As for the related Passerini reaction,12 organic acid isostere
replacement has remained largely unexplored for the Ugi-4CR
as there are only a few examples of isostere use in the Ugi-4CR
for the synthesis of peptidomimetics.5 Therefore, ﬁnding new
isosteres in U-4CR for the synthesis of diverse and complex
peptidomimetic derivatives is of high interest.
We hypothesized that N-hydroxyimides could be used as a
novel acid isostere in the U-4CR reaction, which can directly
provide the α-hydrazino amides as Ugi reaction products. α-
Hydrazino amides are aza analogues of β-peptides and are of
interest for several reasons.13 These foldamers exhibit the
special hydrazino turn, and the hydrazidic bond is very resistant
to protease.14 Hydrazino amides are found in many natural
products such as linatine, a vitamin B6 antagonist;15a
negamycine, an antibiotic;15b and matlystatins, antimicrobial
compounds.15c They also have broad applications in medicinal
chemistry including use as proteasome inhibitors,16a anti-
microbials,16b DNA and RNA interactors,16c (S)-(−)-carbidopa
Received: January 30, 2017
Published: February 21, 2017
Figure 1. Previously reported and new acid isoteres in U-4CR.
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for the treatment of Parkinson’s disease,17 or as human
leukocyte elastase (HLE) inhibitors.18
Hydrazino peptides are mainly synthesized by two methods:
ﬁrst, by using hydrazine derivatives19 and, second, by coupling
of an amino group with another amine typically employing
oxaziridines.14 The general use of hydrazine and oxaziridine is
limited by unavailability of diverse derivatives and their highly
toxic and unstable nature. Another drawback is that their
synthesis is laborious. Therefore, the development of new
methods for the synthesis of this important foldamer is highly
desirable.
Herein, we report the successful use of the N-hydroxyimides
as an acid isostere in the U-4CR for a direct route to the
synthesis of α-hydrazino amides. This is the second example of
cyclic imide migration to nitrogen (O → N imide transfer) in
the Mumm rearrangement to form an N−N bond. This type of
N−O bond breaking and N−N bond formation in a Mumm-
type rearrangement has been recently reported.20 This reaction
illustrates the use of N-hydroxamic acid for N−N bond
formation without phthalimidation.
We started our optimization by using propionaldehyde,
benzylamine, cyclohexyl isocyanide, and N-hydroxyphthali-
mides (NHPI) as model reactants. Reaction in methanol did
not form any desired product (Table 1, entry 1). In polar
aprotic solvents such as THF and CH3CN, only traces of
product were formed (see the Supporting Information for
details of optimization conditions). In the polar protic solvent
MeOH, the U-3CR product, α-amino amide, was formed as a
major product; in contrast, it formed only in trace amounts in
solvents such as THF and toluene. This U-3CR product
formation might be due to the low acidity of N-hydroxyimide
(pKa ∼ 7.5), which functioned only as a catalyst. This
observation led us to try a nonpolar solvent and Lewis acid
to activate N-hydroxyimide for the further optimization.
Indeed, nonpolar solvents such as DCE and toluene allowed
moderate product formation of 25% and 20%, respectively, at
room temperature.
Next, we screened various Lewis acids, (Table S2) such as
InCl3, I2, Sc(OTf)3, etc. (10 mol %) in DCE as a solvent. We
found that ZnCl2 was the best of the screened Lewis acids
(Table 1, entries 7−11). An increase in the temperature failed
to improve the product yield (Table 1, entries 11 and 12). In
further solvent screening with ZnCl2, (Table S3), we observed
that toluene and xylene gave similar yields, 51% and 49%,
respectively (Table 1, entries 13 and 14). The nature of the
solvent played a critical role in the success of the reaction. Next,
we performed a catalyst equivalence study in toluene as solvent.
An increase in the catalyst quantity to 30 mol % gave the best
yield of 66% (Table 1, entry 18). However, a further increase in
the quantity of ZnCl2 to 50 mol % gave a lower yield, 47%
(Table 1, entry 19). The use of sonication in this reaction did
not have any eﬀect on product yield (Table 1, entries 20 and
21).12a
With these optimized conditions in hand, next we examined
the generality of this U-4CR by using various aldehydes,
amines, isocyanides, and N-hydroxyimides (Table 2). Aliphatic
aldehydes oﬀered good yields, up to 78% (Table 2, entries 1−
3). Aromatic aldehydes are also useful substrates in this reaction
(Table 2, entries 6−9).
Electron-withdrawing and -donating groups in aromatic
aldehydes at diﬀerent positions such as ortho and para
provided moderate to good yields. Amines with protected
functional groups like acetal and halogens were well-tolerated in
this reaction, aﬀording moderate to good yields of the products
(Table 2, entries 3, 4, and 6). The acid-protected amino acid β-
alanine ester gave only 18% yield (Table 2, entry 5). Various
aliphatic and aromatic isocyanides like cyclohexyl, phenylethyl,
2-nitrobenzyl, benzyl, 4-methoxyphenyl, and β-cyanoethyl were
well-suited within the developed methodology. Among N-
hydroxyimides, N-hydroxysuccinimides (NHS) also proceeded
smoothly similarly to NHPI and gave 48−59% yield (Scheme 1,
5n−p). However, the reaction with hydroxybenzotriazole
(HOBt) resulted in only trace product formation (Scheme 1,
5q).
A broad functional group tolerance in this reaction could be
of interest for the postmodiﬁcation condensations. Thus,
among the vast number of possible postmodiﬁcation reactions
with this modiﬁed U-4CR, we attempted several. Hydrazines
are important intermediates for the synthesis of many
heterocycles and scaﬀolds.19 The U-4CR product (5d)
treatment with hydrazine hydrate deprotects the NHPI and
forms the free hydrazine derivatives 6.12a We obtained free
hydrazine in a good yield of 64% after overnight reaction
(Scheme 2).
Next, we turned our attention to creating access for
pharmaceutically important α-amino amide molecules. We
converted the U-4CR product (5p) to U-3CR product α-amino
amide 7 in good yield (73%). This AlCl3-catalyzed reaction
cleaved the N−N bond (Scheme 3) to form the ﬁnal product.21
Table 1. Optimization Conditionsa
entry solvent temp (°C) catalyst time (h) % yieldb
1 MeOH rt 12
2 THF rt 12 trace
3 CH3CN rt 12 trace
4 DCE rt 12 25
5 toluene rt 12 20
6c DCE rt ZnCl2 22
7c DCE rt Sc(OTf)3 12 15
8c DCE rt I2 12 22
9c DCE rt TMSCl 12 19
10c DCE rt InCl3 12 10
11c THF 50 I2 12 trace
12c DCE 50 ZnCl2 12 nd
13c toluene rt ZnCl2 12 51
14c xylene rt ZnCl2 12 49
15c chlorobenzene rt ZnCl2 12 31
16c TFE rt ZnCl2 12 38
17d DCE rt ZnCl2 12 40
18d toluene rt ZnCl2 12 66
19e toluene rt ZnCl2 12 47
20f toluene rt ZnCl2 2 43
21g toluene rt ZnCl2 2 50
aThe reaction was carried out with propionaldehyde (1.0 mmol),
benzylamine (1.0 mmol), cyclohexyl isocyanide (1.0 mmol), and N-
hydroxyphthalimide (1.5 mmol) in 2 mL of solvent. bYield of isolated
product 5a. c10 mol % of catalyst used. d30 mol % of ZnCl2 used.
e50
mol % of ZnCl2 used.
fReaction performed in sonication with 10 mol
% of ZnCl2.
gReaction performed in sonication with 30 mol % of
ZnCl2. nd = not determined.
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We did not carry out detailed mechanistic studies but
envision the following mechanism (Scheme 4). ZnCl2 activates
an imine A to allow the nucleophilic addition of isocyanide 3 to
form the nitrilium intermediate C. The hydroxamate
nucleophilicly traps the nitrilium intermediate C. Finally, this
intermediate D undergoes an irreversible Mumm-like N → N
migration to form the α-hydrazino amide 5.
In conclusion, we have reported N-hydroxyimides as novel
acid isosteres in the U-4CR toward the one-step synthesis of α-
hydrazino amides via N−N bond formation. This mild and
general reaction requires catalytic amounts of ZnCl2. This
protocol uses readily available N-hydroxy imides, which replace
Table 2. Substrate Scopea
aReaction conditions: 1 (1.0 mmol), 2 (1.0 mmol), 3 (1.0 mmol), and
4 (1.5 mmol), ZnCl2 (30 mol %) in toluene (2 mL) at rt for overnight.
bIsolated yield. c1.5 equiv of triethylamine used.
Scheme 1. N-Hydroxyimide Scope
Scheme 2. Deprotection toward Hydrazine Formation
Scheme 3. Deprotection toward α-Amino Amide




Org. Lett. 2017, 19, 1228−1231
1230
the toxic and unstable hydrazines/oxaziridine use for the
synthesis of α-hydrazino amides. The method is applicable for a
wide range of aldehydes and amines and has the potential for
multiple postmodiﬁcations. Such scaﬀolds will be useful to ﬁll
the screening decks of the European Lead Factory (ELF).22
Moreover, as this reaction has signiﬁcant potential in
peptidomimetics synthesis, studies on postmodiﬁcation reac-
tions are now in progress.
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